Corey Stephen Cutler, M.D.
This page shows the publications co-authored by Corey Cutler and David Avigan.
A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplant. 2020 04; 55(4):804-810.
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020 06 11; 135(24):2182-2191.
Endogenous thrombopoietin levels are elevated following double cord blood unit transplantation. Bone Marrow Transplant. 2020 06; 55(6):1178-1180.
Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy. 2017 02; 19(2):272-284.
Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53.
Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016 07 07; 128(1):130-7.
Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2014 Dec; 89(12):1092-6.
Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1851-8.
Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011 Dec 01; 365(22):2055-66.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.